Effectiveness of regdanvimab on clinical outcomes in COVID-19 infected patients on hemodialysis

Abstract: Abstracts | i2507 Abstract citation ID: gfae069.1573 #616 Effectiveness of regdanvimab on clinical outcomes in COVID-19 infected patients on hemodialysis Young-Ki Lee1 , Youn Kyung Kee2 , Hayne Cho Park1 , Ajin Cho1 , Do Hyoung Kim1 and Jong-Woo Yoon3 1 Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of South Korea Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Republic of South Korea 3 Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Republic of South Korea 2 Method: We conducted a retrospective study of 230 HD patients hospitalized with COVID-19 infection between December 1, 2020 and November 30, 2021. Of these, 77 (33.5%) were treated with regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group), and 153 (66.5%) did not treat with regdanvimab (non-regdanvimab group). We compared in-hospital mortality rate according to the use of regdanvimab and investigated the factors associated with mortality. Results: The mean age of the patients was 67.9 ± 12.1 years, with 214 (93%) patients aged 50 years or older. There were no significant differences in demographics and comorbidity between the regdanvimab and non-regdanvimab groups. Fifty-nine deaths occurred during hospitalization, 49 (32%) in the non-regdanvimab group and 10 (13%) in the regdanvimab group, and mortality rate was significantly higher in the non-regdanvimab group than that in the regdanvimab group (P=0.001, Fig.). Multivariate Cox regression analysis showed that malignancy (P=0.001), low oxygen saturation<95% at admission (P=0.003), and administration of antibiotics and regdanvimab (P=0.007 and P=0.002, respectively) were significantly associated factors with mortality. Conclusion: Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability of ESKD patients to infection, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD. Figure: Background and Aims: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for the COVID-19 patients with end-stage kidney disease (ESKD). The present study aims to evaluate the effectiveness of regdanvimab on clinical outcomes in COVID-19-infected patients on hemodialysis (HD).